SEC Tracker
Get the app

Inmune Bio INMB

Inmune Bio reported $0 revenue and a $4.72 million loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $4.72 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $16.33 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Inmune Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
  2. For the quarter ended September 30, 2026, Inmune Bio, Inc. reported: Net income -$4.7 million.

2 of 3 claims matched the filing text.

Not found in the filing text

  • The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

From the filing

Item 1. Financial Statements

Item 1. Financial Statements

INMUNE BIO INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

September 30,

2026

December 31,

2025

ASSETS

CURRENT ASSETS

Cash and cash equivalents $ 16,329 $ 24,751

Research and development tax credit receivable 1,211 4,284

Other tax receivable 519 257

Prepaid expenses and other current assets 649 595

TOTAL CURRENT ASSETS 18,708 29,887 Equipment, net 1,189 955

Operating lease – right of use asset 1,080 914

Other assets 531 595

TOTAL ASSETS $ 21,508 $ 32,351 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES

Accounts payable and accrued liabilities $ 2,200 $ 7,768

Accounts payable and accrued liabilities – related party 25 25

Operating lease, current liabilities 692 623 TOTAL CURRENT LIABILITIES 2,917 8,416

Long-term operating lease liabilities 518 411

TOTAL LIABILITIES 3,435 8,827 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY

Preferred stock, $ 0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding - - Common stock, $ 0.001 par value, 200,000,000 shares authorized, 27,915,652 and 26,585,258 shares issued and outstanding, respectively 28 27 Additional paid-in capital 239,324 233,271 Accumulated other comprehensive loss ( 840 ) ( 737 ) Accumulated deficit ( 220,439 ) ( 209,037 ) TOTAL STOCKHOLDERS' EQUITY 18,073 23,524 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 21,508 $ 32,351

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.1

1

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

For the Three Months Ended

September 30,

For the Nine Months Ended

September 30,

2026

2025

2026

2025

REVENUE $ - $ - $ - $ 50 OPERATING EXPENSES

General and administrative 1,846 2,546 6,296 7,115 Research and development 3,163 4,887 6,001 18,330

Impairment of acquired in-process research and development intangible assets - - - 16,514

Total operating expenses 5,009 7,433 12,297 41,959 LOSS FROM OPERATIONS ( 5,009 ) ( 7,433 ) ( 12,297 ) ( 41,909 ) OTHER INCOME, NET 287 961 895 1,240 NET LOSS $ ( 4,7222 ) $ ( 6,472 ) $ ( 11,402 ) $ ( 40,669 ) Net loss per common share – basic and diluted $ ( 0.17 ) $ ( 0.24 ) $ ( 0.42 ) $ ( 1.68 ) Weighted average common shares outstanding – basic and diluted 27,807,917 26,585,258 27,041,706 24,141,613

COMPREHENSIVE LOSS

Net loss $ ( 4,722 ) $ ( 6,472 ) $ ( 11,402 ) $ ( 40,669 ) Other comprehensive loss – foreign currency translation ( 17 ) ( 1 ) ( 103 ) ( 189 ) Total comprehensive loss $ ( 4,739 ) $ ( 6,473 ) $ ( 11,505 ) $ ( 40,858 )

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements .

2

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026

(In thousands, except share amounts)

(Unaudited)

Accumulated

Additional

Other

Total

Common Stock

Paid-In

Subscription

Comprehensive

Accumulated

Stockholders'

Shares

Amount

Capital

Receivable

Gain (Loss)

Deficit

Equity

Balance as of December 31, 2025 26,585,258 $ 27 $ 233,271 $ - $ ( 737 ) $ ( 209,037 ) $ 23,524 Stock-based compensation - - 1,497 - - - 1,497

Gain on foreign currency translation - - - - 10 - 10

Net loss - - - - - ( 5,407 ) ( 5,407 ) Balance as of March 31, 2026 26,585,258 27 234,768 - ( 727 ) ( 214,444 ) 19,624 Common stock issued for cash 370,417 - 584 - - - 584 Stock-based compensation - - 1,358 - - - 1,358 Exercise of warrants for cash 674,155 1 943 ( 814 ) - - 130 Exercise of stock options for cash 23,959 - 35 - - - 35

Loss on foreign currency translation - - - - ( 96 ) - ( 96 )

Net loss - - - - - ( 1,273 ) ( 1,273 ) Balance as of June 30, 2026 27,653,789 28 237,688 ( 814 ) ( 823 ) ( 215,717 ) 20,362 Common stock issued for cash 228,530 - 462 - - - 462 Stock-based compensation - - 1,124 - - - 1,124

Collection of warrant subscription receivable - - - 814 - - 814

Exercise of stock options for cash 33,333 - 50 - - - 50

Loss on foreign currency translation - - - - ( 17 ) - ( 17 )

Net loss - - - - - ( 4,722 ) ( 4,722 ) Balance as of September 30, 2026 27,915,652 $ 28 $ 239,324 $ - $ ( 840 ) $ ( 220,439 ) $ 18,073

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

(In thousands, except share amounts)

(Unaudited)

Accumulated

Additional

Other

Total

Common Stock

Paid-In

Comprehensive

Accumulated

Stockholders'

Shares

Amount

Capital

Loss

Deficit

Equity

Balance as of December 31, 2024 22,280,451 $ 22 $ 195,754 $ ( 575 ) $ ( 163,104 ) $ 32,097 Stock-based compensation - - 2,076 - - 2,076 Sale of common stock for cash 649,860 1 5,272 - - 5,273 Exercise of warrants for cash 100 - 1 - - 1

Loss on foreign currency translation - - - ( 35 ) - ( 35 )

Net loss - - - - ( 9,739 ) ( 9,739 ) Balance as of March 31, 2025 22,930,411 23 203,103 ( 610 ) ( 172,843 ) 29,673 Stock-based compensation - - 1,534 - - 1,534 Sale of common stock for cash 3,654,847 4 22,267 - - 22,271

Loss on foreign currency translation - - - ( 153 ) - ( 153 )

Net loss - - ( 24,458 ) ( 24,458 ) Balance as of June 30, 2025 26,585,258 27 226,904 ( 763 ) ( 197,301 ) 28,867 Stock-based compensation - - 2,984 - - 2,984

Loss on foreign currency translation - - - ( 1 ) - ( 1 )

Net loss - - - - ( 6,472 ) ( 6,472 ) Balance as of September 30, 2025 26,585,258 $ 27 $ 229,888 $ ( 764 ) $ ( 203,773 ) $ 25,378

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements .

4

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

For the Nine Months Ended

September 30,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ ( 11,402 ) $ ( 40,669 )

Adjustments to reconcile net loss to net cash used in operating

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  2. Immucell ICCC public float $51M, Jun 30, 2025
  3. Cue Biopharma CUE public float $52M, Jun 30, 2025
  4. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  5. Precision Biosciences DTIL public float $47M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.